Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
Phase I Study of CM082 Tablets in the Treatment of Advanced Malignant Solid Tumors: Safety, Tolerance and Pharmacokinetics
Sponsor: AnewPharma
A PHASE1 clinical study on Advanced Malignant Solid Tumors, this trial is ongoing. The trial is conducted by AnewPharma and has accumulated 10 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Dec 2024 — Present [monthly]
Unknown PHASE1
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Dec 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Suspended → Active Not Recruiting
-
Dec 2021 — Dec 2022 [monthly]
Suspended PHASE1
Status: Unknown Status → Suspended
▶ Show 5 earlier versions
-
Oct 2021 — Dec 2021 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Apr 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AnewPharma
- Shanghai East Hospital
For direct contact, visit the study record on ClinicalTrials.gov .